Phase I
Making its ASH debut this year was Novartis’ T-Charge CAR-T platform. Novartis presented early data from two first-in-human dose-escalation trials: YTB323 and PHE885.
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
Orca-T demonstrated significantly higher graft-versus-host disease-free, relapse-free survival (GRFS) rates compared to patients who received standard of care.
The following features are highlights from the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in-person in Atlanta, GA, and virtually from December 11 to 14.
Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Shares of Moderna are down nearly 10% this morning despite the company posting positive interim results from an experimental seasonal flu vaccine.
Proof of concept for the Genetically Engineered Microbial Medicines (GEMM) platform came in a recent first-in-human, Phase I trial.
ADI-001 generated positive early responses from three of four evaluable participants, two of whom achieved complete responses while one had a partial response that researchers logged as “near complete.”
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
PRESS RELEASES